Daptomycin* is a lipopeptide antibiotic active against Gram-positive bacteria: Such as Staphylococcus aureus (including methicillinresistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp.equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only).
Indication:Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of Gram-positive bacteria in adult and pediatric patients and treatment of patients with Staphylococcus aureus (including MRSAmethicilin- resistant strains) bacteremia, as well as right-sided endocarditis.
Application: Administered systemically as intravenous infusion or injection.
Product grades |
Non-sterile | ||
Compliance |
No monograph for Daptomycin in either Ph. Eur or USP available |
||
Manufacturing site |
Xellia Pharmaceuticals Ltd., Budapest, Hungary |
||
Release site |
Xellia Pharmaceuticals Ltd., Budapest, Hungary |
||
Site registered |
EU GMP issued by Hungarian National Institute of Pharmacy US FDA |
||
Regulatory documentation |
US Type II Drug Master File (DMF) US Drug Master File (DMF) |
||
Packaging sizes |
|
||
Packaging material |
|
||
Shelf life |
| ||
Storage conditions |
| ||
*Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement.
